Your browser doesn't support javascript.
loading
Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors.
Ma, Yu-Xiang; Liu, Fu-Rong; Zhang, Yang; Chen, Qun; Chen, Zhi-Qiang; Liu, Qian-Wen; Huang, Yan; Yang, Yun-Peng; Fang, Wen-Feng; Xi, Ning; Kang, Ning; Zhuang, Yu-Lei; Zhang, Qi; Jiang, Ying-Zhi; Zhang, Li; Zhao, Hong-Yun.
Afiliação
  • Ma YX; Department of Clinical Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Liu FR; Department of Clinical Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Zhang Y; Department of Clinical Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Chen Q; Department of Clinical Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Chen ZQ; Department of Clinical Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Liu QW; Department of Clinical Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Huang Y; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Yang YP; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Fang WF; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Xi N; HEC R&D Center, Sunshine Lake Pharma Co., Ltd, Donggguan, China.
  • Kang N; HEC R&D Center, Sunshine Lake Pharma Co., Ltd, Donggguan, China.
  • Zhuang YL; HEC R&D Center, Sunshine Lake Pharma Co., Ltd, Donggguan, China.
  • Zhang Q; HEC R&D Center, Sunshine Lake Pharma Co., Ltd, Donggguan, China.
  • Jiang YZ; HEC R&D Center, Sunshine Lake Pharma Co., Ltd, Donggguan, China.
  • Zhang L; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Zhao HY; Department of Clinical Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Front Immunol ; 13: 1024755, 2022.
Article em En | MEDLINE | ID: mdl-36341335
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Proteínas Quinases / Neoplasias Limite: Adult / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Proteínas Quinases / Neoplasias Limite: Adult / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article